Literature DB >> 11534567

Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome.

S Gando1, J Nishihira, S Kobayashi, Y Morimoto, S Nanzaki, O Kemmotsu.   

Abstract

OBJECTIVE: To determine the relations between macrophage migration inhibitory factor (MIF), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and cortisol in patients with systemic inflammatory response syndrome (SIRS) and to determine whether their levels correlate with patient survival.
DESIGN: Prospective, observational, cohort study.
SETTING: General intensive care unit in a university hospital. PATIENTS AND PARTICIPANTS: The study included 17 consecutive patients who met the criteria for SIRS; the patients were classified into subgroups, survivors (n = 8) and nonsurvivors (n = 9); eight healthy volunteers served as control subjects.
INTERVENTIONS: None. MEASUREMENTS AND
RESULTS: Serum MIF, TNF-alpha, IFN-gamma, and cortisol levels were measured serially when the patients were first identified as having SIRS (day 0), and on days 1-4. Except for the high tendency of acute respiratory distress syndrome in nonsurvivors (44%) compared to survivors (13%), there were no differences in the clinical backgrounds of the patients between the two groups. All patients had multiple organ dysfunction syndrome. The values of MIF and TNF-alpha in the nonsurvivors were significantly more elevated than those cytokines measured in the survivors and control subjects. Peak MIF levels significantly correlated with peak TNF-alpha levels (r2 = 0.448, P = 0.002), but did not correlate with peak levels of cortisol and IFN-gamma. Although the levels of IFN-gamma and cortisol showed a marked increase compared to those of the control subjects, we could not find differences in these variables between the survivors and the nonsurvivors.
CONCLUSIONS: High MIF and TNF-alpha levels are closely linked with poor outcome in patients with SIRS. MIF and TNF-alpha may act together and have pathogenic roles in SIRS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11534567     DOI: 10.1007/s001340000818

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  16 in total

1.  Elevation in interleukin 13 levels in patients diagnosed with systemic inflammatory response syndrome.

Authors:  Luis A Socha; John Gowardman; Diego Silva; Manuel Correcha; Nikolai Petrosky
Journal:  Intensive Care Med       Date:  2006-01-26       Impact factor: 17.440

2.  Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor.

Authors:  K Kofoed; J Eugen-Olsen; J Petersen; K Larsen; O Andersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-16       Impact factor: 3.267

3.  Neutrophil dysfunction in steroid-overdosed patients with ulcerative colitis: potential relevance of macrophage migration inhibitory factor to increased postoperative morbidity.

Authors:  Yoshiki Okita; Chikao Miki; Shigeyuki Yoshiyama; Kohei Otake; Toshimitsu Araki; Keiichi Uchida; Masato Kusunoki
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

4.  Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity.

Authors:  Yousef Al-Abed; Christine N Metz; Kai Fan Cheng; Bayan Aljabari; Sonya VanPatten; Steven Blau; Hans Lee; Mahendar Ochani; Valentin A Pavlov; Thomas Coleman; Nathalie Meurice; Kevin J Tracey; Edmund J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

Review 5.  Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor.

Authors:  Susannah K Leaver; Niall S MacCallum; Vasisht Pingle; Matthew B Hacking; Gregory J Quinlan; Timothy W Evans; Anne Burke-Gaffney
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

6.  Macrophage migration inhibitory factor in pediatric patients undergoing surgery for congenital heart repair.

Authors:  Sanah Merchant; Sumekala Nadaraj; Devyani Chowdhury; Vincent A Parnell; Cristina Sison; Edmund J Miller; Kaie Ojamaa
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

Review 7.  The role of macrophage migration inhibitory factor on glucose metabolism and diabetes.

Authors:  C Toso; J A Emamaullee; S Merani; A M J Shapiro
Journal:  Diabetologia       Date:  2008-07-09       Impact factor: 10.122

8.  The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia.

Authors:  Sachin Yende; Derek C Angus; Lan Kong; John A Kellum; Lisa Weissfeld; Robert Ferrell; David Finegold; Melinda Carter; Lin Leng; Zhi-Yong Peng; Richard Bucala
Journal:  FASEB J       Date:  2009-04-03       Impact factor: 5.191

Review 9.  The enigma of sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Peter A Ward
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

10.  High macrophage migration inhibitory factor levels in disseminated intravascular coagulation patients with systemic inflammation.

Authors:  Satoshi Gando; Atsushi Sawamura; Mineji Hayakawa; Hirokatsu Hoshino; Nobuhiko Kubota; Jun Nishihira
Journal:  Inflammation       Date:  2007-05-30       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.